This viewpoint recommends developing an oral vitamin K option to address declining intramuscular prophylaxis rates in newborns, implying health benefits.
This Viewpoint describes rising rates of parent declination of intramuscular vitamin K prophylaxis for newborns and recommends development of a US Food and Drug Administration (FDA)–approved oral formulation.
No takes yet. Share an insight, caveat, or question.
Kair et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: